IONIS PHARMACEUTICALS INC
NASDAQ: IONS (Ionis Pharmaceuticals, Inc.)
Last update: 18 hours ago46.89
-1.26 (-2.62%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ionis Pharmaceuticals, Inc. | Bearish | Mixed |
Stockmoo Score
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tweedy, Browne Co Llc | 30 Jun 2024 | 3,454,676 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (Jefferies, 59.95%) | Buy |
| Median | 60.00 (27.96%) | |
| Low | 37.00 (Goldman Sachs, -21.09%) | Sell |
| Average | 59.09 (26.02%) | |
| Total | 6 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 49.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 26 Aug 2024 | 55.00 (17.30%) | Hold | 46.80 |
| BMO Capital | 02 Aug 2024 | 60.00 (27.96%) | Hold | 49.13 |
| Barclays | 02 Aug 2024 | 51.00 (8.77%) | Hold | 49.13 |
| Goldman Sachs | 02 Aug 2024 | 37.00 (-21.09%) | Sell | 49.13 |
| Guggenheim | 02 Aug 2024 | 70.00 (49.29%) | Buy | 49.13 |
| Needham | 02 Aug 2024 | 60.00 (27.96%) | Buy | 49.13 |
| 22 Jul 2024 | 60.00 (27.96%) | Buy | 50.61 | |
| Leerink Partners | 24 Jul 2024 | 62.00 (32.22%) | Buy | 50.74 |
| B of A Securities | 23 Jul 2024 | 68.00 (45.02%) | Buy | 50.43 |
| 16 Jul 2024 | 67.00 (42.89%) | Buy | 49.84 | |
| TD Cowen | 23 Jul 2024 | 59.00 (25.83%) | Buy | 50.43 |
| Jefferies | 16 Jul 2024 | 75.00 (59.95%) | Buy | 49.84 |
| Stifel | 27 Jun 2024 | 53.00 (13.03%) | Hold | 47.23 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GEARY RICHARD S | - | 49.58 | -651 | -32,277 |
| Aggregate Net Quantity | -651 | |||
| Aggregate Net Value ($) | -32,277 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 49.58 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GEARY RICHARD S | Officer | 29 Aug 2024 | Automatic sell (-) | 331 | 49.90 | 16,517 |
| GEARY RICHARD S | Officer | 28 Aug 2024 | Automatic sell (-) | 320 | 49.25 | 15,760 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |